| http://www.w3.org/ns/prov#value | - IMPACT was a double blind, randomized, multicenter, placebo-controlled trial in 512 patients with metastatic castration resistant prostate cancer conducted under a Special Protocol Assessment with the FDA. Placebo was used as a control as opposed to chemotherapy with the intent of creating a clinical niche for the development of treatments which prolonged survival while causing few treatment-relat
|
